- Home
- RLTY vs GOSS Comparison
RLTY vs GOSS Comparison
Compare RLTY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | GOSS |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.3M | 726.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RLTY | GOSS |
|---|---|---|
| Price | $14.43 | $3.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 86.7K | ★ 4.0M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.38 | $0.76 |
| 52 Week High | $14.60 | $3.87 |
Technical Indicators
Market Signals| Indicator | RLTY | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 33.68 | 51.00 |
| Support Level | $14.28 | $3.37 |
| Resistance Level | $14.69 | $3.87 |
| Average True Range (ATR) | 0.17 | 0.26 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 19.51 | 18.94 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.